Shanghai-based ZAI Lab has in-licensed China rights for HM61713, a tumor-targeting EGFR tyrosine kinase inhibitor from South Korea's Hanmi, which has racked up an impressive string of license deals this year.
South Korea's Samsung Bioepis said its biosimilar drug Benepali, used in the treatment of rheumatoid arthritis and other autoimmune diseases, has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.
Indonesia's Kalbe Farma has signed a deal with South Korea's Genexine in which it will invest $9.1 million to develop biopharmaceutical products and create an R&D laboratory in Indonesia to research the hormone erythropoietin, which helps produce red blood cells, according to a report by the Nikkei Asian Review.
South Korea biotech Genexine has put together a second deal in Asia this month, licensing out 5 protein therapies with a subsidiary of China's Tasly Pharmaceutical worth a potential $125 million and which follows a joint venture plan with Indonesia's Kalbe Farma.
China biotech 3SBio said it has signed an exclusive licensing deal with South Korea's Alteogen for the development, manufacturing and marketing of ALT-P7, an antibody-drug conjugate used in cancer treatments, keeping it on a steady deal streak since a public relisting this summer.
South Korea's SK Chemicals said domestic sales of the country's first cell-culture flu vaccine, SKYCellflu, passed 1 million doses within two weeks of launch. Plans for sales abroad are also in the cards.
A thwarted challenge from an activist investor to block the $8 billion merger of Samsung C&T and Cheil Industries last week has set the stage for family-controlled Samsung Electronics and related units to focus on boosting already rapid growth at Samsung BioLogics and Samsung Bioepis, the Korea Herald reports.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
South Korea has set out plans to spend an additional KRW10 trillion ($9 billion) to manage the outbreak of Middle East respiratory syndrome that has afflicted 179 and caused 27 deaths since May, news reports said.
Two South Korean firms, Corestem and Kyongbo Pharmaceutical, this week showed solid investor demand for biopharma stocks in the country.